AlphaStocks
6.1
Consider Buy

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Health Care / Biotechnology

S&P 500

$447.14

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#262out of 1127 in Health Care

Is VERTEX PHARMACEUTICALS INC / MA a Good Investment in 2026?

VERTEX PHARMACEUTICALS INC / MA (VRTX) scores 6.1 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Lynch model rates VERTEX PHARMACEUTICALS INC / MA as Strong (PEG 0.7 · Fast Grower). However, the Graham model rates it Caution — Significantly above fair value. VERTEX PHARMACEUTICALS INC / MA currently trades below its estimated fair value of $456, suggesting potential upside. VERTEX PHARMACEUTICALS INC / MA ranks #262 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E29.2ROE22.0Market Cap115B

Estimated Fair Value

$456.282% below

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Strong

PEG 0.7 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is VERTEX PHARMACEUTICALS INC / MA (VRTX) a good investment?
Based on AlphaStocks' composite analysis, VERTEX PHARMACEUTICALS INC / MA (VRTX) scores 6.1 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading near estimated fair value.
What is VERTEX PHARMACEUTICALS INC / MA's Piotroski F-Score?
VERTEX PHARMACEUTICALS INC / MA's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is VRTX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $456, VRTX appears undervalued. The stock currently trades 2% below its estimated fair value. Trading near estimated fair value.
How does VRTX compare to other Health Care stocks?
VERTEX PHARMACEUTICALS INC / MA ranks #262 out of 1127 stocks in the Health Care sector, placing it in the top 23% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about VRTX?
AlphaStocks evaluates VRTX using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Strong. These models are combined into a single composite score of 6.1/10.

Similar Stocks

PARRFTIAZN

Compare VRTX with

VRTX vs PARRVRTX vs FTIVRTX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer